407 related articles for article (PubMed ID: 12088172)
1. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
[TBL] [Abstract][Full Text] [Related]
2. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
3. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
4. [Reduction of prolonged QTc-interval related risks in treatment with neuropharmacological drugs. Recommendations for clinical practice].
van de Kraats GB; Slob J; Tenback DE
Tijdschr Psychiatr; 2007; 49(1):43-7. PubMed ID: 17225205
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medications and cardiac conduction risks.
Roman M; Farmer SY
Issues Ment Health Nurs; 2010 Jan; 31(1):68-70. PubMed ID: 19951166
[No Abstract] [Full Text] [Related]
6. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic agents associated with QT interval prolongation.
Olsen KM
J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
[TBL] [Abstract][Full Text] [Related]
8. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
Kecskeméti V
Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
[TBL] [Abstract][Full Text] [Related]
9. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
Lawrence KR; Nasraway SA
Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
12. Droperidol, QT prolongation, and sudden death: what is the evidence?
Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
14. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
15. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
17. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
18. Long QT syndrome caused by noncardiac drugs.
Viskin S; Justo D; Halkin A; Zeltser D
Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
[TBL] [Abstract][Full Text] [Related]
19. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for treating cardiac manifestations of organophosphates poisoning with special emphasis on long QT and Torsades De Pointes.
Bar-Meir E; Schein O; Eisenkraft A; Rubinshtein R; Grubstein A; Militianu A; Glikson M;
Crit Rev Toxicol; 2007 Mar; 37(3):279-85. PubMed ID: 17453935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
